HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): David R. Jones Frank C. Detterbeck Thomas M. Egan Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, D. R. Articles by Tepper, J. E. Search for Related Content PubMed PubMed Citation Articles by Jones, D. R. Articles by Tepper, J. E. Related Collections Related Article

Ann Thorac Surg 1997;64:185-192
© 1997 The Society of Thoracic Surgeons

---

Original Articles: General Thoracic

Induction Chemoradiotherapy Followed by Esophagectomy in Patients With Carcinoma of the Esophagus

Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, North Carolina

Background. Induction chemoradiotherapy followed by esophagectomy may provide results superior to those of single-modality treatment in patients with esophageal cancer. The purpose of this study was to review our experience with this approach for esophageal cancer.

Methods. From 1988 to 1996, 166 consecutive patients with esophageal cancer were evaluated; 66 entered a protocol of chemotherapy (5-fluorouracil, cisplatin) concurrent with radiation (45 Gy) followed by esophagectomy. Fifty-four patients completed the protocol.

Results. Toxicity associated with induction chemoradiotherapy was minimal. The actuarial survival at 12, 24, and 36 months was 59%, 42%, and 32%, respectively. The pathologic complete response (pCR) rate was 41%, with 12-, 24-, and 36-month survivals of 77%, 50%, and 45%, whereas non-pCR patients had survivals of 46%, 35%, and 23%. The difference in survival between pCR and non-pCR patients was not significant (p = 0.13), but the difference in recurrence-free survival was significant (p = 0.007).

Conclusions. This well-tolerated protocol resulted in a high pCR. Trimodality treatment for esophageal cancer may provide long-term survival in some patients regardless of their pCR status.

Related Article

Discussion
Ann. Thorac. Surg. 1997 64: 191-192. [Extract] [Full Text]

This article has been cited by other articles:

				C. Schieman, D. A. Wigle, C. Deschamps, F. C. Nichols III, S. D. Cassivi, K. R. Shen, and M. S. Allen Salvage Resections for Recurrent or Persistent Cancer of the Proximal Esophagus After Chemoradiotherapy Ann. Thorac. Surg., February 1, 2013; 95(2): 459 - 463. [Abstract] [Full Text] [PDF]

				S.-H. Li, K.-M. Rau, H.-I. Lu, Y.-M. Wang, W.-Y. Tien, J.-L. Liang, and W.-C. Lin Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma Eur J Cardiothorac Surg, December 1, 2012; 42(6): 958 - 964. [Abstract] [Full Text] [PDF]

				A. Herskovic, W. Russell, M. Liptay, M. J. Fidler, and M. Al-Sarraf Esophageal carcinoma advances in treatment results for locally advanced disease: review Ann. Onc., May 1, 2012; 23(5): 1095 - 1103. [Abstract] [Full Text] [PDF]

				N. P. Rizk, E. Venkatraman, M. S. Bains, B. Park, R. Flores, L. Tang, D. H. Ilson, B. D. Minsky, and V. W. Rusch American Joint Committee on Cancer Staging System Does Not Accurately Predict Survival in Patients Receiving Multimodality Therapy for Esophageal Adenocarcinoma J. Clin. Oncol., February 10, 2007; 25(5): 507 - 512. [Abstract] [Full Text] [PDF]

				B. Agarwal, S. G. Swisher, J. Ajani, K. Kelly, R. R. Komaki, E. Abu-Hamda, A. M. Correa, and J. A. Roth Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic Gastroesophageal Reflux Ann. Thorac. Surg., May 1, 2005; 79(5): 1716 - 1723. [Abstract] [Full Text] [PDF]

				A. F. Isik, G. Ozturk, S. Ugras, and M. Karaayvaz Enzymatic dissection for palliative treatment of esophageal carcinoma: an experimental study Interact CardioVasc Thorac Surg, April 1, 2005; 4(2): 140 - 142. [Abstract] [Full Text] [PDF]

				J. S. Donington, D. L. Miller, M. S. Allen, C. Deschamps, F. C. Nichols III, and P. C. Pairolero Preoperative chemoradiation therapy does not improve early survival after esophagectomy for patients with clinical stage III adenocarcinoma of the esophagus Ann. Thorac. Surg., April 1, 2004; 77(4): 1193 - 1199. [Abstract] [Full Text] [PDF]

				M. Koshy, N. Esiashvilli, J. C. Landry, C. R. Thomas Jr., and R. H. Matthews Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches Oncologist, April 1, 2004; 9(2): 147 - 159. [Abstract] [Full Text] [PDF]

				J. S. Donington, D. L. Miller, M. S. Allen, C. Deschamps, F. C. Nichols III, and P. C. Pairolero Tumor response to induction chemoradiation: influence on survival after esophagectomy Eur J Cardiothorac Surg, October 1, 2003; 24(4): 631 - 637. [Abstract] [Full Text] [PDF]

				M. RIEDEL, H. J. STEIN, L. MOUNYAM, F. ZIMMERMANN, U. FINK, and J. R. SIEWERT Influence of Simultaneous Neoadjuvant Radiotherapy and Chemotherapy on Bronchoscopic Findings and Lung Function in Patients with Locally Advanced Proximal Esophageal Cancer , November 1, 2000; 162(5): 1741 - 1746. [Abstract] [Full Text]

				M. A. Chidel, T. W. Rice, D. J. Adelstein, P. A. Kupelian, J. H. Suh, and M. Becker Resectable Esophageal Carcinoma: Local Control with Neoadjuvant Chemotherapy and Radiation Therapy Radiology, October 1, 1999; 213(1): 67 - 72. [Abstract] [Full Text]